Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Core Insights - Vor Bio is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases [2] - The company is advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development [2] Event Participation - Vor Bio will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025 [1] - The fireside chat will take place from 4:00-4:25 pm ET and will be available via live webcast and archived replay on the company's website [1]